Article Text

Download PDFPDF
Tumor Boost Using External Beam Radiation in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy: Outcome From a Multicenter Retrospective Study (Korean Radiation Oncology Group 1419)
  1. Haeyoung Kim, MD*,
  2. Young Seok Kim, MD,
  3. Ji Hyeon Joo, MD,
  4. Keun-Yong Eom, MD,
  5. Won Park, MD§,
  6. Jin Hee Kim, MD,
  7. Jong Hoon Lee, MD,
  8. Yeon Sil Kim, MD#,
  9. Seok Ho Lee, MD**,
  10. Kijung Ahn, MD††,
  11. Yong Bae Kim, MD‡‡,
  12. Me-Yeon Lee, MD§§ and
  13. Sei Kyung Chang, MD∥∥
  1. *Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong;
  2. Asan Medical Center, University of Ulsan College of Medicine, Seoul;
  3. Seoul National University Bundang Hospital, Seoungnam;
  4. §Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul;
  5. Dongsan Medical Center, Keimyung University School of Medicine, Daegu;
  6. St Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon;
  7. #The Catholic University of Korea, Seoul;
  8. **Gacheon University Gil Hospital, Incheon;
  9. ††Inje University College of Medicine, Busan;
  10. ‡‡Yonsei Cancer Center, Yonsei University College of Medicine, Seoul;
  11. §§Hallym University Sacred Heart Hospital, Anyang; and
  12. ∥∥CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  1. Address correspondence and reprint requests to Haeyoung Kim, MD, Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, 7, Keunjaebong-gil, Hwaseong-si, Gyeonggi-do 18450, Republic of Korea. E-mail: hykim0131@hanmail.net.

Abstract

Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy.

Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012.

Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40–54 Gy) for whole pelvis and 24 Gy (range, 9–35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%.

Conclusions Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.

  • Brachytherapy
  • Radiotherapy
  • Uterine cervical neoplasm

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.